A phase 3, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geography atrophy secondary to age-related macular degeneration
Baruch Kuppermann, MD, PhD
The Gavin Herbert Eye Institute.
The purpose of this study is to compare the effects, good or bad, of lampalizumab versus sham (false) injection on you and your Geographic Atrophy (GA) and also to see if lampalizumab works differently in people with specific inherited (genetic) characteristics with an increased risk of AMD.
Males and females, 50 years of age or older at the screening visit, diagnosed Geographic Atrophy (GA) secondary to age-related macular degeneration in both eyes.
Participation will include a total of up to 27 visits and will take about two hours of the subject’s time at each visit over the next 24 months.
Taking part in this study may or may not make a subject’s health better. While researchers hope the study drug will be more effective than the standard (usual) treatment, there is no proof of this yet. A subject’s condition may also get worse.
Subjects will receive $50 for each completed visit.